Gemcitabine (Gemzar) / tumCV Cancer Research Results

GEM, Gemcitabine (Gemzar): Click to Expand ⟱
Features: Chemo
GEM An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA
Treats cancer of pancreas, lung, ovary and breast.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Inhibition of DNA synthesis (antimetabolite effect) Incorporated into DNA → chain termination Normal dividing cells affected (bone marrow, GI epithelium) P, R, G Direct cytotoxicity Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is phosphorylated to the triphosphate form (dFdCTP) which competes with dCTP, gets incorporated into DNA, and blocks DNA chain elongation.
2 Ribonucleotide reductase (RNR) inhibition dFdCDP inhibits RNR → deoxynucleotide pool depletion ↔ (normal proliferating cells also impacted) R, G Nucleotide pool imbalance Gemcitabine diphosphate (dFdCDP) inhibits RNR, reducing available dNTPs and enhancing the chain-termination effect.
3 Apoptosis induction (DNA damage response) DNA damage signaling → caspase activation Toxicity in dividing normal tissues G Execution of cell death Prolonged DNA synthesis arrest and replication stress triggers apoptosis pathways via ATR/Chk1, p53, and caspase cascades.
4 Cell-cycle arrest (S-phase accumulation) S-phase arrest steers cells into apoptosis ↔ G Cytostasis → death Accumulation of stalled replication forks enforces S-phase arrest and amplifies cytotoxicity.
5 DNA damage response signaling (ATR/Chk1/Chk2) Checkpoint activation ↔ R, G Damage signaling Replication stress activates ATR/Chk1/Chk2 and modulates cell-cycle checkpoints and repair responses.
6 NF-κB pro-survival signaling (resistance axis) NF-κB activation can reduce sensitivity ↔ R, G Resistance/modulation In some tumor models, NF-κB and other pro-survival axes mediate resistance to gemcitabine cytotoxicity; inhibition sensitizes cells.
7 Autophagy modulation (response to stress) Autophagy ↑ in some contexts (cytoprotective) ↔ G Adaptive stress response Gemcitabine can induce autophagy as a survival mechanism in some models; autophagy inhibition can sensitize cells in combination studies.
8 Reactive oxygen species (ROS) elevation (indirect) ROS ↑ (reported in some models) ↔ G Stress amplification Some preclinical studies report ROS increases secondary to replication stress; not a primary mechanism but modulates cell-death pathways.
9 Clinical resistance mechanisms (CDA, nucleoside transporters) CDA ↑; hENT1 ↓ correlates with resistance — G Resistance / exposure constraint Cytidine deaminase (CDA) inactivates gemcitabine; lower hENT1 transport reduces uptake — major clinical resistance factors.
10 Bioavailability / pharmacokinetics (IV dosing; systemic exposure) IV infusion achieves systemic levels ↔ — PK constraint Gemcitabine is given systemically (often IV) and achieves cytotoxic blood levels; rapid deamination by CDA and short half-life shape dosing.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid biochemical activation / early metabolic engagement)
  • R: 30 min–3 hr (acute nucleotide pool effects / checkpoint signaling)
  • G: >3 hr (DNA damage response, cell death, phenotype outcomes)
tumCV, Cell Viability: Click to Expand ⟱
Source:
Type:
Cell Viability
Scientific Papers found: Click to Expand⟱
2750- BetA,  GEM,    Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation
- in-vitro, PC, Bxpc-3 - in-vitro, Lung, H1299
CHK1↓, ChemoSen↑, tumCV↓, Apoptosis↑, DNAdam↑,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
5084- SSE,  GEM,    The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
- in-vitro, PC, PANC1 - vitro+vivo, PC, Panc02
tumCV↓, ChemoSen↑, TumCG↓, OS↑, MMP↓, AIF↑, GSH↓, Trx↓, ROS↑, AntiTum↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   NQO1?, 1,   ROS↑, 1,   Trx↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   CDC25↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

PDHB↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 3,   BAX↑, 1,   cl‑Casp3↑, 1,   p‑Chk2↑, 1,   TUNEL↑, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   tumCV↓, 4,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DNAdam↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT?, 1,   HDAC↓, 1,   TumCG↓, 2,  

Migration ⓘ

Ki-67↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

eNOS↓, 1,   Hif1a↓, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 3,   eff↑, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 1,  
Total Targets: 36

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: tumCV, Cell Viability
4 Gemcitabine (Gemzar)
1 Betulinic acid
1 Metformin
1 Sulforaphane (mainly Broccoli)
1 Selenite (Sodium)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:84  Target#:897  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page